journal article·2025-06-18

Spatiotemporal Circadian Oscillator Manipulation for Enhanced Ovarian Cancer Therapy Using a Versatile Nanoplatform

Jiamin Lin, Qiang Zhang, Yanlin Xin, Kaixin Lin, Ziao Zhou, Xitong Yang, Yitian Zhou, Yuhua Wang, Jun Li, Hao Yang, Zejuan Xie, Wenli Lu, Zhiqiang Bi, Yuanyuan Guo, Jiuming Zheng, Jiajia Shen, Xi Yang, Jianliang Shen, Ruogu Qi

ACS Applied Materials & Interfaces· Volume 17· Issue 24
Publisher page

Abstract

Circadian rhythm (CR) disruption has been confirmed as a contributing factor to tumor progression. However, regulating circadian genes shows an inhibitory effect on ovarian tumor initiation and progression, which highlights the urgent necessity to regulate tumors’ CR to understand their role in ovarian cancer (OC) therapy precisely. Herein, a novel near-infrared (NIR) light-controlled spatiotemporal strategy is presented, aiming to manipulate ovarian tumors’ CR while enhancing the efficacy of chemotherapy agents. To achieve this strategy, a versatile nanoplatform (NP PEG-CS ) that integrates the modified photothermal sensitizer IR-820 and a norcantharidin-platinum(IV) prodrug conjugate onto a cationic polyethylenimine (PEI) backbone coated with PEG-modified chondroitin sulfate (PEG-CS) for targeted delivery to ovarian tumors is designed. NP PEG-CS effectively diminishes the CR amplitude upon NIR illumination, demonstrating its potential for innovative cancer treatment strategies. Additionally, molecular analyses reveal that this disruption involves calcium-mediated influx, triggered by the photothermal properties of NP PEG-CS . When combined with chemotherapeutic agents, a disrupted clock can elevate tumor sensitivity to these drugs. This process effectively increases DNA-Pt adducts, reduces the activity of protein phosphatase 2A (PP2A), and promotes cell cycle arrest, synergistically amplifying DNA damage and inducing robust tumor apoptosis. The novel nanoparticle synergism offers innovative insights into harnessing CR as a therapeutic target for more effective cancer management.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Circadian rhythm and melatonin · Nanoplatforms for cancer theranostics · Neurobiology and Insect Physiology Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Medicine

Nanjing University of Chinese Medicine

Department of General Surgery, The Sixth Affiliated Hospital

Sun Yat-sen University

College of Life Science

Yulin University

Department of Pharmacy

Ji’an Central People’s Hospital

Ningbo Taikang Hospital

Department of Neurosurgery, Ren Ji Hospital

Shanghai Jiao Tong University School of Medicine

Wenzhou Institute, University of Chinese Academy of Sciences, State Key Laboratory of Ophthalmology

Wenzhou Medical University

Funding

National Natural Science Foundation of China · Jiangsu Key Discipline Construction Fund of the 14th Five-Year Plan · jiangsu Innovation Project of Graduate Student

References (60)

Show source-provided references
1. 10.3322/caac.2183410.3322/caac.21834 ↗
2. 10.3322/caac.2182010.3322/caac.21820 ↗
3. 10.1007/s00280-017-3501-810.1007/s00280-017-3501-8 ↗
4. 10.3322/caac.2145610.3322/caac.21456 ↗
5. 10.1038/s41571-024-00881-310.1038/s41571-024-00881-3 ↗
6. 10.1136/bmj.m377310.1136/bmj.m3773 ↗
7. 10.2147/OTT.S15542510.2147/OTT.S155425 ↗
8. 10.1016/j.bioorg.2019.10292510.1016/j.bioorg.2019.102925 ↗
9. 10.2147/JEP.S26738310.2147/JEP.S267383 ↗
10. 10.1002/advs.20230121610.1002/advs.202301216 ↗
11. 10.1016/j.celrep.2024.11428110.1016/j.celrep.2024.114281 ↗
12. 10.1016/j.ccr.2021.21399110.1016/j.ccr.2021.213991 ↗
13. 10.32604/or.2024.03100610.32604/or.2024.031006 ↗
14. 10.1016/S0092-8674(00)00205-110.1016/S0092-8674(00)00205-1 ↗
15. 10.1126/science.817132510.1126/science.8171325 ↗
16. 10.1101/gad.249417.11410.1101/gad.249417.114 ↗
17. 10.1016/j.tcb.2021.06.00810.1016/j.tcb.2021.06.008 ↗
18. 10.1080/15384101.2018.155863810.1080/15384101.2018.1558638 ↗
19. 10.1073/pnas.221482912010.1073/pnas.2214829120 ↗
20. 10.1530/ERC-20-039010.1530/ERC-20-0390 ↗
21. 10.1080/0001634080234828610.1080/00016340802348286 ↗
22. 10.2147/CMAR.S27890310.2147/CMAR.S278903 ↗
23. 10.3389/fmolb.2023.120813210.3389/fmolb.2023.1208132 ↗
24. 10.1186/1740-3391-9-610.1186/1740-3391-9-6 ↗
25. 10.1186/s12964-021-00721-210.1186/s12964-021-00721-2 ↗
26. 10.1158/0008-5472.CAN-17-403410.1158/0008-5472.CAN-17-4034 ↗
27. 10.1111/j.1471-4159.2009.06223.x10.1111/j.1471-4159.2009.06223.x ↗
28. 10.1038/ncomms1083710.1038/ncomms10837 ↗
29. 10.1016/j.jconrel.2023.12.00210.1016/j.jconrel.2023.12.002 ↗
30. 10.1016/j.bioactmat.2023.11.01710.1016/j.bioactmat.2023.11.017 ↗
31. 10.1016/j.cej.2022.13750010.1016/j.cej.2022.137500 ↗
32. 10.1002/adma.20231231610.1002/adma.202312316 ↗
33. 10.3389/fnmol.2021.66667310.3389/fnmol.2021.666673 ↗
34. 10.1046/j.1471-4159.2001.00270.x10.1046/j.1471-4159.2001.00270.x ↗
35. 10.1073/pnas.050107610210.1073/pnas.0501076102 ↗
36. 10.1101/gad.237511.11410.1101/gad.237511.114 ↗
37. 10.1016/j.molmet.2015.09.00410.1016/j.molmet.2015.09.004 ↗
38. 10.1021/acsnano.6b0665110.1021/acsnano.6b06651 ↗
39. 10.1016/j.jconrel.2016.05.06210.1016/j.jconrel.2016.05.062 ↗
40. 10.1039/C4NR00708E10.1039/C4NR00708E ↗
41. 10.1021/nn900904h10.1021/nn900904h ↗
42. 10.1021/ja900591t10.1021/ja900591t ↗
43. 10.1002/mabi.20090029710.1002/mabi.200900297 ↗
44. 10.1002/idm2.1221010.1002/idm2.12210 ↗
45. 10.1021/acs.bioconjchem.0c0013510.1021/acs.bioconjchem.0c00135 ↗
46. 10.1002/adhm.20220000410.1002/adhm.202200004 ↗
47. 10.1038/s41467-023-38128-x10.1038/s41467-023-38128-x ↗
48. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
49. 10.1007/s00018-009-0053-z10.1007/s00018-009-0053-z ↗
50. 10.1016/j.bbcan.2023.18890010.1016/j.bbcan.2023.188900 ↗
51. 10.1016/j.jmb.2020.01.01910.1016/j.jmb.2020.01.019 ↗
52. 10.1096/fj.12-20578110.1096/fj.12-205781 ↗
53. 10.1002/cbf.287110.1002/cbf.2871 ↗
54. 10.1158/1541-7786.MCR-20-072210.1158/1541-7786.MCR-20-0722 ↗
55. 10.1093/jb/mvn16710.1093/jb/mvn167 ↗
56. 10.1073/pnas.090593010610.1073/pnas.0905930106 ↗
57. 10.1016/j.apsb.2024.02.02410.1016/j.apsb.2024.02.024 ↗
58. 10.1016/j.semcancer.2022.03.00110.1016/j.semcancer.2022.03.001 ↗
59. 10.1016/j.eng.2024.01.00110.1016/j.eng.2024.01.001 ↗
60. 10.1016/S0968-0896(99)00313-210.1016/S0968-0896(99)00313-2 ↗